Journal Watch · Frontiers in Immunology · 2026

The role of CD36 in immune function: bridging innate and adaptive responses.

By evaluating emerging research and clinical trials, this review proposes innovative approaches for exploiting CD36's therapeutic potential, aiming to inspire further research and development in disease treatment.

Zhang X, Luo LJ, Wu YW, Chen LFrontiers in Immunology3 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1728509PMID: 41676141Study type: review / perspective

TL;DR

By evaluating emerging research and clinical trials, this review proposes innovative approaches for exploiting CD36's therapeutic potential, aiming to inspire further research and development in disease treatment.

Key findings

  • We highlight novel insights into CD36 as a therapeutic target, presenting recent advances in targeting strategies for a spectrum of conditions such as inflammatory diseases, infections, metabolic disorders and cardiovascular diseases.
  • By evaluating emerging research and clinical trials, this review proposes innovative approaches for exploiting CD36's therapeutic potential, aiming to inspire further research and development in disease treatment.

What they did

This comprehensive review synthesizes current research to elucidate CD36's integral functions within the immune system, including its involvement in phagocytosis, inflammation, and the crucial interplay between innate and adaptive immune responses.

Full abstract (original)

Background: CD36 is a multifunctional glycoprotein essential in fatty acid metabolism, angiogenesis, and atherogenesis, playing a critical role in immunological processes.

What they did: This comprehensive review synthesizes current research to elucidate CD36's integral functions within the immune system, including its involvement in phagocytosis, inflammation, and the crucial interplay between innate and adaptive immune responses.

Results & conclusions: We highlight novel insights into CD36 as a therapeutic target, presenting recent advances in targeting strategies for a spectrum of conditions such as inflammatory diseases, infections, metabolic disorders and cardiovascular diseases. By evaluating emerging research and clinical trials, this review proposes innovative approaches for exploiting CD36's therapeutic potential, aiming to inspire further research and development in disease treatment.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1728509 · PubMed 41676141.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

By evaluating emerging research and clinical trials, this review proposes innovative approaches for exploiting CD36's therapeutic potential, aiming to inspire further research and development in disease treatment.

What type of study is this?

It is a review / perspective, published in Frontiers in Immunology in 2026. This comprehensive review synthesizes current research to elucidate CD36's integral functions within the immune system, including its involvement in phagocytosis, inflammation, and the crucial interplay between innate and adaptive immune responses.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1728509. PubMed ID: 41676141. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang X, Luo LJ, Wu YW, Chen L. The role of CD36 in immune function: bridging innate and adaptive responses.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1728509.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-role-of-cd36-in-immune-function-bridging-innate-and-adaptive-respons-728509/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides